| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Total revenue | $9.7M-26.5% | $13.2M-30.5% | $18.9M-43.3% | $33.4M+67.9% | $19.9M+250.5% | $5.7M-53.1% | $12.1M |
| Intangible asset amortization - cost of revenue | $10.7M-7.7% | $11.6M-37.4% | $18.5M-4.2% | $19.3M | — | — | — |
| Total cost of revenue | $154.6M+4.7% | $147.6M+12.4% | $131.4M+8.7% | $120.9M | — | — | — |
| Gross profit | $362.5M+21.6% | $298.1M+29.8% | $229.7M+30.7% | $175.7M | — | — | — |
| Research and development | $70.8M+2.2% | $69.3M+20.9% | $57.3M+41.1% | $40.6M+36.1% | $29.8M+73.5% | $17.2M+15.8% | $14.9M |
| Selling and marketing | $100.2M+5.0% | $95.4M-6.0% | $101.5M+4.0% | $97.6M+22.2% | $79.8M+52.4% | $52.4M-2.4% | $53.7M |
| General and administrative | $110.8M+0.2% | $110.6M+28.3% | $86.2M+17.8% | $73.2M-27.8% | $101.4M+175.9% | $36.7M+26.5% | $29.0M |
| Impairment of assets | $20.5M+508.8% | $3.4M-95.1% | $68.3M+1959.9% | $3.3M | $0 | — | — |
| Total operating expenses | $304.8M+8.1% | $282.0M-10.6% | $315.5M+45.5% | $216.8M-28.1% | $301.4M+97.2% | $152.9M+12.8% | $135.5M |
| Income (loss) from operations | $57.8M+257.9% | $16.1M+118.8% | -$85.8M-108.8% | -$41.1M+49.8% | -$81.9M-131.4% | -$35.4M-133.9% | -$15.1M |
| Other income, net | $10.4M+8.6% | $9.6M+4.6% | $9.2M+97.3% | $4.7M+1732.3% | $254K-47.1% | $480K-81.0% | $2.5M |
| Income (loss) before income taxes | $68.2M+164.9% | $25.7M+133.6% | -$76.6M-110.3% | -$36.4M+55.4% | -$81.6M-133.9% | -$34.9M-177.1% | -$12.6M |
| Income tax provision (benefit) | $1.8M+15.1% | $1.6M+172.7% | -$2.2M-1760.2% | $133K+102.2% | -$6.1M | $0 | $0 |
| Net income (loss) | $66.4M+174.9% | $24.1M+132.4% | -$74.4M-103.5% | -$36.6M+51.6% | -$75.6M-116.5% | -$34.9M-177.1% | -$12.6M |
| Basic (in USD per share) | $840.00+162.5% | $320.00+131.4% | -$1020.00-100.0% | -$510.00+54.1% | -$1110.00-168081.8% | -$0.66-144.4% | -$0.27 |
| Diluted (in USD per share) | $820.00+164.5% | $310.00+130.4% | -$1020.00-100.0% | -$510.00+54.1% | -$1110.00-168081.8% | -$0.66-144.4% | -$0.27 |
| Basic (in shares) | 78.58B+2.7% | 76.48B+5.3% | 72.64B+1.5% | 71.55B+5.4% | 67.89B+127419.4% | 53.2M+15.4% | 46.1M |
| Diluted (in shares) | 80.57B+3.1% | 78.16B+7.6% | 72.64B+1.5% | 71.55B+5.4% | 67.89B+127419.4% | 53.2M+15.4% | 46.1M |
| Testing revenue | |||||||
| Cost of revenue | $7.6M-38.8% | $12.4M-19.2% | $15.3M-16.9% | $18.4M+91.1% | $9.7M+1454.4% | $621K | $0 |
| Product revenue | |||||||
| Biopharmaceutical and other revenue | |||||||
| Intangible Asset Amortization | |||||||
| Intangible asset amortization - operating expenses | $2.5M-24.6% | $3.3M+56.6% | $2.1M+1.2% | $2.1M | — | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.